Cannabis Users with First-Episode Psychosis Had Lower Metabolic Syndrome Rates

Among 404 first-episode psychosis patients, those who used cannabis at any point during the study were less likely to develop metabolic syndrome and tended to have better triglyceride and HDL cholesterol profiles.

Stiles, Erik et al.·Early intervention in psychiatry·2021·Moderate EvidenceRetrospective Cohort
RTHC-03554Retrospective CohortModerate Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Retrospective Cohort
Evidence
Moderate Evidence
Sample
N=404

What This Study Found

In the RAISE-ETP program (n=404), cannabis users had similar baseline metabolic syndrome rates as abstainers but showed lower triglycerides, elevated HDL, and were less likely to develop metabolic syndrome over the study period.

Key Numbers

404 participants in RAISE-ETP; similar baseline metabolic syndrome rates; cannabis users had lower triglycerides and higher HDL; cannabis users less likely to develop metabolic syndrome over study period.

How They Did This

Retrospective analysis of 404 participants in the Recovery After Initial Schizophrenia Episode-Early Treatment Program (RAISE-ETP), using multiple logistic regression to examine the association between cannabis use and metabolic syndrome.

Why This Research Matters

Metabolic syndrome is a major concern for psychosis patients on antipsychotics. If cannabis use is associated with lower metabolic risk, understanding the mechanism could lead to new approaches for managing medication side effects.

The Bigger Picture

This finding adds to a growing body of evidence suggesting cannabis may have metabolic effects that counteract some of the weight and lipid changes caused by antipsychotic medications, though the clinical implications remain unclear.

What This Study Doesn't Tell Us

Retrospective design; potential confounders including diet, exercise, and medication adherence; cannabis use was not randomized; cannot determine causal mechanism.

Questions This Raises

  • ?Is the metabolic benefit due to cannabis itself or to behavioral differences among users?
  • ?Could cannabinoid-based interventions help manage antipsychotic-related metabolic syndrome?

Trust & Context

Key Stat:
Cannabis users with first-episode psychosis were less likely to develop metabolic syndrome
Evidence Grade:
Retrospective analysis of a well-characterized treatment program, limited by observational design and potential confounders.
Study Age:
Data from the RAISE-ETP program.
Original Title:
Cannabis use and metabolic syndrome among clients with first episode psychosis.
Published In:
Early intervention in psychiatry, 15(4), 1051-1055 (2021)
Database ID:
RTHC-03554

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-ControlFollows or compares groups over time
This study
Cross-Sectional / Observational
Case Report / Animal Study

Looks back at existing records to find patterns.

What do these levels mean? →

Frequently Asked Questions

Does cannabis protect against metabolic syndrome?

In this study of first-episode psychosis patients, cannabis users had lower triglycerides, higher HDL, and lower rates of metabolic syndrome. However, the study cannot prove cannabis caused these benefits, and other factors may explain the association.

What is metabolic syndrome?

A cluster of conditions including high blood pressure, high blood sugar, excess body fat, and abnormal cholesterol that increase the risk of heart disease, stroke, and diabetes. It is a common side effect of antipsychotic medications.

Read More on RethinkTHC

Cite This Study

RTHC-03554·https://rethinkthc.com/research/RTHC-03554

APA

Stiles, Erik; Alcover, Karl C; Stiles, Bryan; Oluwoye, Oladunni; McDonell, Michael G. (2021). Cannabis use and metabolic syndrome among clients with first episode psychosis.. Early intervention in psychiatry, 15(4), 1051-1055. https://doi.org/10.1111/eip.13030

MLA

Stiles, Erik, et al. "Cannabis use and metabolic syndrome among clients with first episode psychosis.." Early intervention in psychiatry, 2021. https://doi.org/10.1111/eip.13030

RethinkTHC

RethinkTHC Research Database. "Cannabis use and metabolic syndrome among clients with first..." RTHC-03554. Retrieved from https://rethinkthc.com/research/stiles-2021-cannabis-use-and-metabolic

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.